XRAY Stock Analysis — Dentsply Sirona
Sector: Healthcare
AI Verdict
XRAY is cheap for the sector, but the low multiple reflects real doubts about its ability to reignite growth despite its entrenched dental equipment moat.
Competitive Moat
Dentsply Sirona manufactures dental equipment and consumables, benefiting from entrenched relationships with dental practices and a broad product portfolio that creates switching costs. Its scale and integration across imaging, CAD/CAM, and treatment centers make it difficult for smaller competitors to match its breadth.
Summary
XRAY’s forward P/E of 8.0x is far below the healthcare sector median of 22x, making valuation the central story.
Where It Stands
With a forward P/E of 8.0x and trailing revenue down -1.0%, XRAY trades at a steep discount to the healthcare sector’s 22x median but faces growth headwinds.
Key Metrics
- Forward P/E: 8.0x
- Revenue Growth: -0.0%
- Dividend Yield: 0.05%
- 52-Week High: $17.09
- 52-Week Low: $9.85
Analyst Consensus
8 Buy · 12 Hold · 2 Sell (22 analysts)
Bull Case
At 8.0x next year’s earnings, investors are paying a fraction of sector norms for a company with deep dental industry ties.
Bear Case
With revenue shrinking -1.0% year-over-year, even a modest P/E re-rating to 12x (still well below sector) would mean a 50% price gain that requires a turnaround story not yet visible in the numbers.
Catalyst to Watch
Watch for any return to positive revenue growth in quarterly results, as even flat or modestly positive sales could trigger a valuation re-rate.